SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Mobileye Global, Inc. engages in the business of developing and deploying driver assistance systems and autonomous driving technologies and solutions. It operates under the Mobileye and Other segments. The company was founded by Amnon Shashua and Ziv Aviram in 1999 and is headquartered in Jerusalem, Israel.

Mobileye Global Inc - Ordinary Shares - Class A

MOBILEYE GLOBAL INC

Mobileyes quarterly results beat expectations and modestly raised its full-year outlook, but the stock is selling off to a new 52-week low. Traders are split between short sellers focused on weak revenue trends and competitive risks, and bulls who see the cash balance and buyback authorization as support for an undervalued business.

Basic Attention Token (BAT) is a cryptocurrency launched in 2017and operates on the Ethereum platform. Basic Attention Token has a current supply of 1,500,000,000 with 1,495,724,656.95260575 in circulation. The last known price of Basic Attention Token is 0.13064027 USD and is up 2.94 over the last 24 hours. It is currently trading on 591 active market(s) with $15,372,551.09 traded over the last 24 hours. More information can be found at https://basicattentiontoken.org/.

Basic Attention Token

BATs sharp move higher is drawing attention as traders point to technical breakout momentum and a broader pickup in altcoins; no specific token-related catalyst is clearly confirmed. The community is largely bullish on continuation, while others warn about profit-taking and a possible pullback after the rally.

Helus Pharma, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is drawing attention ahead of the expected Q4 Phase 3 topline readout for HLP003, its investigational adjunctive treatment for major depressive disorder. Traders are split between optimism that positive data could validate the program and concern about the binary trial risk, potential dilution, and recent weak price action.

TRON (TRX) is a cryptocurrency launched in 2018. TRON has a current supply of 95,020,742,700.022444 with 95,020,750,177.733244 in circulation. The last known price of TRON is 0.3287714 USD and is down -6.58 over the last 24 hours. It is currently trading on 1389 active market(s) with $1,904,975,878.16 traded over the last 24 hours. More information can be found at https://trondao.org/.

Tron

TRON is drawing attention for a sharp decline and underperforming other altcoins that traders describe as green; bearish chart setups and talk of a corrective pullback contrast with holders viewing the weakness as a pause in its longer-term climb.

United States Natural Gas Fund LP. - United States Natural Gas Fund

United States Natural Gas Fund, LP

Natural gas weakness tied to mild-weather forecasts and ample storage is the dominant topic, with traders noting the price slide and looking for lower entry points. Some are buying dips in anticipation of winter cold or a sharp weather-driven rebound, while others remain bearish on warm-winter risk and persistent supply.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

A quarterly earnings beat and higher full-year sales outlook, driven by demand for Mounjaro and Zepbound, have fueled LLYs advance to record highs. Traders are largely bullish on the growth, while some question the valuation and point to lower profit guidance from acquisition charges and weaker Foundayo sales amid competition in oral obesity drugs.

Nu Holdings Ltd. is a holding company, which engages in the provision of digital banking services. The company was founded by David Vélez Osorno, Cristina Helena Zingaretti Junqueira, and Adam Edward Wible on February 26, 2016 and is headquartered in São Paulo, Brazil.

Nu Holdings Ltd - Ordinary Shares Class A

Nu Holdings Ltd

Nu is selling off alongside Brazilian equities after Lulas reelection prompted investors to reassess the countrys political and fiscal outlook; traders note the move appears macro-driven rather than tied to new company news. The community is divided between viewing the drop as an overreaction and buying opportunity and worrying about Nus heavy exposure to Brazil and the risks of its policy environment.

Chainlink (LINK) is a cryptocurrency launched in 2017and operates on the Ethereum platform. Chainlink has a current supply of 1,000,000,000 with 748,099,970.42488396 in circulation. The last known price of Chainlink is 11.42916419 USD and is up 8.20 over the last 24 hours. It is currently trading on 2313 active market(s) with $611,471,639.23 traded over the last 24 hours. More information can be found at https://chain.link/.

ChainLink

LINK is drawing attention for a sharp rebound and renewed buying momentum, with traders watching whether it can clear resistance and sustain a breakout. Bulls are accumulating and pointing to Chainlinks role in institutional tokenization and interoperability, while skeptics warn that the rally could fade and question whether network adoption translates into value for the token.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

A reported major Binance security breach has fueled crypto-market concern and Bitcoin selling, weighing on Strategy as a Bitcoin proxy. Traders are split between viewing the selloff as a buying opportunity and warning of further downside; Q3 revenue concerns and the CFO transition add to the bearish debate.

Hut 8 Corp. engages in the development and operation of data centers at scale, supporting AI, high-performance computing (HPC), ASIC compute, and other energy-intensive technology applications. It operates through the following segments: Power, Digital Infrastructure, Compute, and Others. The Power segment manages the origination, development, and management of powered land and energy infrastructure. The Digital Infrastructure refers to the development, ownership, and operation of facilities designed to support next-generation, energy-intensive technology application. The Compute segment deals with operating businesses that deploy and monetize compute assets across next-generation energy-intensive technology. The Others segment offers equipment sales and repairs. The company was founded on January 27, 2023 and is headquartered in Miami, FL.

Hut 8 Corp

Hut 8 is drawing attention amid a sharp selloff across data-center and AI-infrastructure stocks, as traders debate concerns about AI demand, project financing, execution risk, and higher yields. Bears see further downside and question the companys ability to turn its buildout into profits, while bulls call the decline an overreaction and point to long-term data-center demand and HUTs Bitcoin exposure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CervoMed Shows Progress in Treating Rare Aphasia Condition

CervoMed reports a promising reduction in neuronal damage biomarkers during the first 12 weeks of its Phase 2a trial for neflamapimod.read more...

Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue Estimates

Janux Therapeutics (JANX) delivered earnings and revenue surprises of -34.62% and -72.33%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

EyePoint (EYPT) Reports Q2 Loss, Beats Revenue Estimates

EyePoint (EYPT) delivered earnings and revenue surprises of -18.48% and +102.80%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

CRVO Stock Rockets Nearly 100% On Patent Win Before Offering News Cools Rally

Equity

The new patent for neflamapimod covers the treatment of dementia with Lewy bodies in patients without significant signs of Alzheimer’s disease.


Emerging Growth Stocks Enter Breakout Territory

A wave of high-impact developments is drawing investor attention as multiple emerging growth companies advance toward potentially transformative milestones. $CRVO, $NTHI, $CAST, $LNKS, $BFLY, $QS, $APWC

Brains, AI Imaging, and Breakthrough Antibiotics Ignite Investor Buzz

The healthcare and biotechnology sector continues to generate a steady stream of meaningful catalysts as companies advance novel therapies, secure regulatory milestones, strengthen intellectual property portfolios, and expand commercialization efforts. Recent developments from CervoMed (NASDAQ:CRVO), Butterfly Network (NYSE:BFLY), NeOnc (NASDAQ:NTHI), Spero Therapeutics (NASDAQ:SPRO), GSK (NYSE:GSK), and IceCure Medical (NASDAQ:ICCM) highlight several emerging themes shaping the sector, including neurodegenerative disease treatment, AI-powered diagnostics, antimicrobial resistance, minimally invasive cancer care, and synthetic biology.

Power Hour Breakouts: Clinical Catalysts and New Highs Send Traders Hunting for the Next Winner

Clinical milestones, regulatory progress, insider buying, and newly public biotechnology platforms are among the leading themes for today’s power hour. $CRVO, $NTHI, $SLBT, $SPCX, $WULF, $AMAT, $EW, $OSCR

Biotech Bulls Stampede as Clinical Wins and Milestones Fuel Momentum

Multiple clinical-stage companies are delivered meaningful regulatory, clinical, and corporate milestones. From brain cancer drug development and cell therapy expansion to neurodegenerative disease programs and cardiovascular breakthroughs, investors were presented with a wave of catalysts that are driving enthusiasm across several emerging healthcare names. Traders appeared particularly focused on companies advancing toward late-stage clinical development, securing new regulatory clearances, or gaining broader visibility through public market events. $NTHI, $SLBT, $CRVO, $EWTX

Why Did CRVO Stock Crash 22% In Pre-Market Trading Today?

CervoMed announced a $10.5 million private placement financing, with participation from institutional healthcare investors and company insiders.

Pelthos Therapeutics Inc. (PTHS) Reports Q1 Loss, Beats Revenue Estimates

Pelthos Therapeutics Inc. (PTHS) delivered earnings and revenue surprises of +22.75% and +12.03%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

CervoMed, Inc. is a clinical stage biotechnology company. It engages in the business of advancing CNS focused therapeutics to benefit patients with a range of degenerative diseases of the brain. The company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha. CervoMed, Inc. was founded in1995 and is headquartered in Boston, MA.

CervoMed Inc

Bearish Sentiment

<ul class="summary-bullets"><li>Neflamapimod is an oral drug that works by reducing inflammation and damage in the brain.</li><li>CervoMed needs additional funding or a partnership to move forward with a late-stage trial.</li><li>Separately, the company announced it is raising $10 million by selling 2.5 million new shares of its common stock at $4 per share.</li></ul><p>Shares of CervoMed Inc. (CRVO) soared 95% on Thursday before paring gains after the company announced it had received approval for a new U.S. patent that protects the use of its lead drug neflamapimod.</p><p>The new patent covers the treatment of dementia with Lewy bodies in patients who do not show significant signs of Alzheimer’s disease. There are currently no approved treatments for dementia with Lewy bodies in the United States or Europe. The protection is expected to run into 2042.</p><p>The stock started paring gains after the company announced a direct offering of its common stock, in a bid to raise capital. At the time of writing, the stock was up 14%.</p><h2 class="st-heading-2">CRVO Eyes Next Step For Neflamapimod</h2><p>Neflamapimod is an oral drug that works by reducing inflammation and damage in the brain. The company recently completed a mid-stage study in patients with dementia with Lewy bodies who fit this profile. In late 2025, CervoMed reached an agreement with the FDA on a potential path to approval for the drug in this condition. A larger late-stage study is planned but will require additional funding or a partnership to move forward.</p><p>CervoMed is also testing neflamapimod in other brain disorders, including certain types of frontotemporal dementia and ALS. Early data from one of these studies is expected later this year.</p><h2 class="st-heading-2">CRVO Announces Capital Raise</h2><p>Separately, CervoMed announced it is raising $10 million by selling 2.5 million new shares of its common stock at $4.00 per share. The company said it plans to use the money for working capital and general corporate purposes. The offering is expected to close around June 22.</p><h2 class="st-heading-2">How Did CRVO Retail Traders React?</h2><p>On Stocktwits, retail sentiment around CRVO stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.</p><p>A Stocktwits user said they see the stock pare gains.</p><p><stembedurl>https://www.stocktwits.com/Princess88/message/656867945</stembedurl></p><p>According to data from Koyfin, all seven analysts covering CRVO rate it a 'Buy.' The stock has a 12-month average price target of $19.50, representing a potential upside of about 412% from the stock’s last close.</p><p><a href="https://stocktwits.com/symbol/CRVO">CRVO stock</a> has fallen about 15% this year.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/kmx-stock-recoups-earnings-day-losses-analysts-pour-praise-on-new-car-max-ceo-s-focus-on-cost-and-customer-experience/cZKka7dR77Z">KMX Stock Recoups Earnings Day Losses – Analysts Pour Praise On New CarMax CEO’s Focus On Cost And Customer Experience</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the CervoMed (Cervo Med) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

The new patent for neflamapimod covers the treatment of dementia with Lewy bodies in patients without significant signs of Alzheimer’s disease.

Vanguard Total Stock Market ETF

Vanguard Extended Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$1.60
Prev Close	$1.75
Open	$1.71
Dividend Yield	0.00%
50-Day Moving Average	$2.55
Beta	1.47
Avg. Volume	183,521.39
PE Ratio	-0.50

52-Week High	$10.00
52-Week Low	$1.60
Market Capitalization	$24.19M
EPS (Annual)	-$2.98
Price to Book	0.94
Revenue Per Employee	$267,100.67

Feed

News

Sentiment

Earnings

Fundamentals

Info

CRVO Fundamentals